



(12) Translation of
European patent specification

(11) NO/EP 3366293 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/4375 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.07.27
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.03.11
(86)	European Application Nr.	17208408.9
(86)	European Filing Date	2012.06.07
(87)	The European Application's Publication Date	2018.08.29
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Deciphera Pharmaceuticals, LLC, 643 Massachusetts, Suite 200, Lawrence, Kansas 66044, USA
(72)	Inventor	FLYNN, Daniel L., 4165 Blackjack Oak Drive, Lawrence, KS 66047, USA KAUFMAN, Michael D., 4708 Muirfield Drive, Lawrence, KS 66047, USA PETILLO, Peter A., 1424 N. 960 Road, Lawrence, KS 66046, USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
(56)	References Cited:	US-A1- 2008 114 006 WO-A1-2008/051757

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En forbindelse for bruk i behandling av en sykdom forårsaket av kinase-aktiviteten av c-KIT, onkogene former derav, eller polymorfe derav, hos en pasient med behov for dette, hvor sykdommen er valgt fra gruppen bestående av gastrointestinale stromale tumorer, ovarier kreft, melanom, akutt myeloid leukemi, kimcelle tumorer av seminom eller dysgerminom, teratomer, mastocytose og mastcelleleukemi, omfattende å administrere til pasienten en terapeutisk effektiv mengde av en forbindelse valgt fra gruppen bestående av:

1-(4-klor-3-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-(3-cyanfenyl)urea, 1-(3-cyanfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(2-fluor-4-metyl-5-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(2,4-difluor-5-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)urea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-(3-fluorfenyl)urea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-fenylurea, 1-(3-klorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(3-cyanfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea, 1-(4-klor-2-fluor-5-(1-isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-fenylurea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)-3-fenylurea, 1-[4-klor-5-(1-etyl-7-metylamino-2-okso-1,2-dihydro-[1,6]naftyridin-3-yl)-2-fluor-fenyl]-3-(3-fluor-fenyl)-urea, 1-[4-kloro-5-(1-etyl-7-metylamino-2-okso-1,2-dihydro-[1,6]naftyridin-3-yl)-2-fluor-fenyl]-3-(2-fluor-fenyl)-urea, 1-(4-klor-3-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(4-klor-5-(7-(2-(dimetylamino)etylamino)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(7-(3-(dimetylamino)propylamino)-1-etyl-2-

okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-brom-5-(1-ethyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(4-klor-5-(1-ethyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)urea, 1-(4-klor-3-(1-ethyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-fenylurea, 1-(4-klor-5-(1-ethyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(4-fluorfenyl)urea, 1-(4-klor-5-(1-ethyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(2-fluorfenyl)urea, 1-(5-(1-ethyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-fenylurea, 1-(5-(1-ethyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-fenylurea, 1-(5-(1-ethyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(2-fluorfenyl)urea, 1-(4-klor-5-(1-ethyl-7-(3-metoksypropylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(2,4-difluor-5-(1-isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-(3-fluorfenyl)urea, 1-(2-fluor-5-(1-isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(4-klor-5-(1-ethyl-2-okso-7-(tetrahydro-2H-pyran-4-ylamino)-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, (S)-1-(4-klor-5-(1-ethyl-7-(1-metoksypropan-2-ylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(5-(1-ethyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-(syklopropylamino)-1-ethyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(4-klor-5-(1-ethyl-7-(1-metylpiperidin-4-ylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5)-(1-ethyl-2-okso-7-(THF-3-ylamino)-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4)-klor-5-(1-ethyl-7-(2-(metylsulfonyl)etylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-ethyl-7-(1-metylpyrrolidin-3-ylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-brom-5-(1-ethyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(4-brom-5-(1-ethyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-brom-5-(1-ethyl-7-(2-(metylsulfonyl)etylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(5-(7-acetamido-1-ethyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl)-3-fenylurea, 1-(5-(7-acetamido-1-ethyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-ethyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-, 5-difluorfenyl)urea, 1-(4-brom-2-fluor-5-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-fenylurea, 1-(5-(7-

amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl 3-
 fenylurea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-
 metylfenyl)-3-(3-fluorfenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea,
 1-(3,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-
 naftyridin-3-yl)-2-fluor-4-metylfenyl)urea, 1-(2,5-difluorfenyl)-3-(5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea,
 1-(2,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-
 naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(3,5-difluorfenyl)-3-(5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, N-(3-
 (2-brom-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-
 7-yl)-2-cyanacetamid, N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-
 1,2-dihydro-1,6-naftyridin-7-yl)-2-cyanacetamid,
 1-(5-(7-acetamido-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-
 difluorfenyl)-3-fenylurea, N-(3-(2-klor-5-(3-(3,5-difluorfenyl)ureido)-4-fluorfenyl)-
 1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, 1-(4-klor-5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(2,5-
 difluorfenyl)urea, 1-(3-kloro-5-fluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-
 1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea, 3-(3-(2-klor-4-fluor-5-
 (3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-
 dimetylurea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-
 naftyridin-3-yl)-2-fluorfenyl)-3-(3-klor-5-fluorfenyl)urea, 1-(4-klor-5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluor-5-
 metylfenyl)urea, metyl(3-(2-klor-4)-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-
 1,2-dihydro-1,6-naftyridin-7-yl)karbamat, N-(3-(2-klor-4)-fluor-5-(3-fenyl-
 ureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-2-metoksyacetamid,
 2-cyan-N-(3-(2,4-difluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-
 naftyridin-7-yl) acetamid, 1-(4-cyan-5-(1-etyl-7-(metylamino)-2-okso-1,2-
 dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-2-fluor-5-(1-
 isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-(3-
 fluorfenyl)urea, N-(1-etyl-3)-(4-fluor-5-(3-(3-fluorfenyl)ureido)-2-metylfenyl)-2-
 okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, 1-(4)-klor-5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-((4-
 metylpiperazin-1-yl)metyl)fenyl)urea, N-(1-etyl-3-(4-fluor-2-metyl-5-(3-
 fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, N-(3-(2-klor-
 4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-3-
 hidroksyazetid-1-karboksamid, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-
 dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-((4-metyl-piperazin-1-
 yl)metyl)fenyl)urea, 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-

naftyridin-3-yl)-2-fluorfenyl)-3-(3-((4-metylpiperazin-1-yl)metyl)-fenyl)urea, (R)-
 N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-
 naftyridin-7-yl)-3-(dimetylamino)pyrrolidin-1-karboksamid, (S)-N-(3-(2-klor-4-
 fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-
 5 yl)pyrrolidin-2-karboksamid, N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-
 isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, 1-(4-klor-5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(4-fluor-3-
 ((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-
 okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluor-5-((4-
 10 metylpiperazin-1-yl)metyl)fenyl)urea,
 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-
 metylfenyl)-3-(4-fluor-3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(5-(1-etyl-7-
 (metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-(4-fluor-
 3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(4-klor-5-(1-etyl-7-(metylamino)-
 15 2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-cyanfenyl)urea, 1-(4-
 klor)-5-(1-etyl-7-((3-morfolinopropyl)amino)-2-okso-1,2-dihydro-1,6-naftyridin-3-
 yl)-2-fluorfenyl)-3-fenylurea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-
 naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(4-fluor-3-((4-metylpiperazin-1-
 yl)metyl)fenyl)urea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-
 20 naftyridin-3-yl)-2-fluorfenyl)-3-(3-((dimetylamino)metyl)-4-fluorfenyl)urea, 1-(4-
 klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-
 fluorfenyl)-3-(4-fluor-3-(morfolinometyl)fenyl)urea, (S)-N-(3-(2-klor-4-fluor-5-(3-
 fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-3-
 (dimetylamino)pyrrolidin-1-karboksamid, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-
 25 okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(4-fluor-3-(pyrrolidin-1-
 ylmetyl)fenyl)urea, 3-(3-(2-klor-4-fluor-5-(3-(3-fluorfenyl)ureido)fenyl)-1-
 isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(2-klor-4-
 fluor-5-(3-(3-fluorfenyl)ureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-
 naftyridin-7-yl)acetamid, N-(1-etyl-3-(4-fluor-5-(3-(4-fluor-3-((4-metylpiperazin-
 1-yl)metyl)fenyl)ureido)-2-metyl-fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)
 30 formamid, 3-(1-etyl-3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-
 dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(2-klor-4-fluor-5-(3-
 fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-3-
 (dimetylamino)azetidin-1-karboksamid, 3-(3-(2-klor-4-fluor-5-(3-
 35 fenylureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-
 dimetylurea, 3-(3-(5-(3-(benzo[b]tiofen-3-yl)ureido)-4-fluor-2-metylfenyl)-1-etyl-
 2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, 3-(3-(2-brom-4-fluor-5-
 (3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-
 dimetylurea, 3-(1-etyl-3-(4-fluor-5-(3-(3-fluorfenyl)ureido)-2-metyl-fenyl)-2-

okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(2-klor-4-fluor-5-(3-(4-fluor-3-(morfolinometyl)fenyl)ureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl) formamid, 3-(3-(5-(3-(3,5-difluorfenyl)ureido)-4-fluor-2-metylphenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)azetidin-1-karboksamid, N-(1-etyl-3-(4-fluor-2)-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)azetidin-1-karboksamid, 1-(5-(1-etyl-7-((6-metylpyridin-3-yl)amino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)-3-fenylurea, 3-(3-(2,4-difluor-5)-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, 3-(dimetylamino)-N-(1-etyl-3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)azetidin-1-karboksamid, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-jodfenyl)-3-fenylurea, og 1-(5-(1-etyl-7-((1-metyl-1H-pyrazol-4-yl)amino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)-3-fenylurea.

2. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av:

1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)-3-fenylurea, 1-[4-kloro-5-(1-etyl-7-metylamino-2-okso-1,2-dihydro-[1,6]naftyridin-3-yl)-2-fluorfenyl]-3-(3-fluor-fenyl)-urea, 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)urea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)urea, 3-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(1-etyl-3-(4-fluor-5-(3-(3-fluorfenyl)ureido)-2-metylphenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, N-(1-etyl-3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, og 3-(1-etyl-3-(4-fluor-2-metyl-5)-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea.

3. Forbindelse for bruk ifølge krav 1, hvor c-KIT, onkogene former derav eller polymorfe derav, kinase-aktivitet derav som forårsaker sykdommen, inneholder en missense-

mutasjon, innsetting-mutasjon eller en delesjon-mutasjon kodet av eksoner omfattende Ekson 9, Ekson 11, Ekson 13, Ekson 14, Ekson 17 eller Ekson 18, som presenteres enten individuelt eller i kombinasjon.

5 4. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-fenyl)-3-fenylurea.

5. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)-3-fenylurea.

10

6. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylphenyl)urea.

15

7. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl)-3-fenylurea.

8. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea.

20

9. Forbindelse for bruk ifølge krav 4, hvor sykdommen er gastrointestinale stromale tumorer.

10. Forbindelse for bruk ifølge krav 4, hvor sykdommen er melanom.

25

11. Forbindelse for bruk ifølge krav 4, hvor sykdommen er mastocytose.

12. Forbindelse for bruk ifølge krav 4, hvor sykdommen er akutt myeloid leukemi.

30

13. Forbindelse for bruk ifølge krav 4, hvor sykdommen er mastcelleleukemi.

14. En forbindelse som er 1-(3,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea.

35

15. En farmasøytisk sammensetning omfattende forbindelsen ifølge krav 14 eller et salt derav, sammen med en farmasøytisk akseptabel bærer, hvor bæreren inkluderer et tilsetningsstoff valgt fra gruppen bestående av adjuvanter, eksipienser, diluenter og stabilisatorer.